Over the last few weeks, we’ve highlighted some of the top COVID-19 vaccine stocks.

And most have done incredibly well – with the exception of Gilead Sciences (GILD).

Look at BioNTech (BNTX) for example.

Just weeks ago, it and Pfizer said they’ve begun delivering doses of their experimental coronavirus vaccines for initial human testing in the United States, says CNBC.  “If the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.”

Since then, the BNTX stock has run from a low of $43 to a high of $60.17.  As BNTX and Pfizer push forward, we wouldn’t be shocked to see BNTX near $80.

Inovio Pharmaceuticals (INO)

After strong results in animal trials, INO now hopes to see even better results in humans.  To date, the company has enrolled 40 healthy volunteers in Phase 1 trials, and expects to post preliminary data by late June 2020.

Patients will receive two doses of the vaccine four weeks apart. If results are as positive as the company may be able to move to Phase 2/3 trials by summer pending approval. The company is also in Phase 1/2 human trials for the vaccine in South Korea after receiving $6.9 million in funding from the Coalition of Epidemic Preparedness (CEPI).

Since the start of May 2020, INO has run from a low of $9.53 to a high of $14.17.

Moderna Inc. (MRNA)

Moderna has been the most explosive.  Since the start of May 2020, MRNA has run from a low of $46.29 to a recent high of $87 before pulling back..  All on news its vaccine produced COVID-19 antibodies in all 45 of its participants.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],” Tal Zaks, the chief medical officer at Moderna said, as quoted by CNBC.

“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” he added.